BC
PTCT icon

Birchview Capital’s PTC Therapeutics PTCT Stock Holding History

Birchview Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14,900
Closed -$483K – 43
2015
Q4 		$483K Sell
14,900
-2,000
-12% -$58.9K 0.28% 23
2015
Q3 		$451K Hold
16,900
– – 0.29% 25
2015
Q2 		$813K Hold
16,900
– – 0.43% 20
2015
Q1 		$1.03M Sell
16,900
-3,000
-15% -$183K 0.54% 18
2014
Q4 		$1.03M Buy
+19,900
New +$876K 0.6% 17

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Birchview Capital's PTCT Position: Q1 2016 in Review

Birchview Capital sold out of PTC Therapeutics (PTCT) in Q1 2016, closing a stake of 14,900 shares — an estimated $483K sold.

Birchview Capital first reported a position in PTCT in Q4 2014 and held it in 5 quarters. The position peaked at $1.03M in Q4 2014. 119 funds tracked by Wall St. Rank hold PTCT as of Q1 2016.

  • Birchview Capital reported no remaining PTC Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Birchview Capital sold 14,900 PTC Therapeutics shares in Q1 2016, an estimated $483K.
  • Birchview Capital first reported a position in PTC Therapeutics in Q4 2014 and held it in 5 quarters.
  • Birchview Capital's PTC Therapeutics position peaked at $1.03M in Q4 2014.
  • 119 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2016.

Based on Birchview Capital's 13F filing for Q1 2016, filed 28 Apr 2016.